LTRN Lantern Pharma
Lantern Pharma (LTRN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: May 12, 2026 , by KEYSER D JEFFREY .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| KEYSER D JEFFREY | Director | Buy | 48,544 | $2.06 | $100.0K | 94,303 | |
| Schalop Lee Troy | Director | Buy | 48,544 | $2.06 | $100.0K | 48,544 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.